Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Core Insights - Cognition Therapeutics, Inc. announced that abstracts from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for presentation at the Alzheimer's Association's International Conference in Philadelphia from July 28-August 1, 2024 [1][2] Study Details - The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial enrolling approximately 144 patients with mild-to-moderate Alzheimer's disease, with participants randomized to receive either placebo or CT1812 at doses of 100 mg or 300 mg daily for six months [3] - The study endpoints include safety, cognitive function measured by the ADAS-Cog 11 scale, and biomarker evidence of disease modification, supported by approximately $30 million in grants from the National Institute on Aging [3] Drug Information - CT1812 is an experimental orally delivered small molecule that selectively binds to the sigma-2 receptor complex, displacing toxic Aβ oligomers, which are implicated in Alzheimer's disease progression [4] - The sigma-2 receptor complex is involved in regulating cellular processes that are damaged by toxic interactions with Aβ oligomers and oxidative stress, leading to cognitive impairment [4] Ongoing Studies - The company is currently recruiting participants for the START study of CT1812 in early Alzheimer's disease and the MAGNIFY study in adults with geographic atrophy due to dry age-related macular degeneration [5] - Enrollment has completed in the SHIMMER study of CT1812 in adults with dementia with Lewy bodies and the SHINE study [5] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [6] - The company is investigating CT1812 in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration, with a belief that targeting the sigma-2 receptor represents a distinct mechanism from other current treatment approaches [6]